NovaBay reassures investors of liquidity level

• Issuing a letter to investors, NovaBay Pharmaceuticals (NYSE:NBY) said that the current liquidity level of the company would be sufficient to support its 2021 operations. The company shares are up ~12.0% in premarket.
• NovaBay focused on non-antibiotic anti-infective products also announced the upcoming launch of its consumer products Avenova^® and CelleRx^® Clinical Reset in brick-and-mortar retail stores.
• While Avenova will be available at CVS stores, CelleRx Clinical Reset will reach U.S. and Chinese consumers through select luxury retailers, the company said.
• As of Q3 2020, NovaBay’s cash and equivalents stood at $13.4M, ~94.2% higher than the level in 2019 year-end.